

Combined ETA/ETB receptor blockade of human peritoneal mesothelial cells inhibits collagen I RNA synthesis

STANISLAO MORGERA, JULIANE SCHLENSTEDT, PIA HAMBACH, MARKUS GIESSING, SERDAR DEGER, BERTHOLD HOCHER, and HANS-HELLMUT NEUMAYER

Department of Nephrology, Charité, Humboldt University of Berlin, Berlin, Germany; Department of Urology, Charité, Humboldt University of Berlin, Berlin Germany

Combined ETA/ETB receptor blockade of human peritoneal mesothelial cells inhibits collagen I RNA synthesis.

Background. Peritoneal fibrosis is a serious complication of peritoneal dialysis; however, the mechanisms are poorly understood. We studied osmolarity and physical stress-induced effects on collagen I RNA synthesis in human peritoneal mesothelial cells (HPMCs) and focused on endothelin as a possible mediator.

Methods. HPMC were grown in a medium containing either D-glucose or glycerol to analyze the impact of osmolarity on mesothelial endothelin-1 (ET-1) release and on collagen I RNA synthesis [reverse transcription-polymerase chain reaction (RT-PCR)]. A cellular model of nonlaminar fluid shear stress and cellular stretch was used to analyze the effects of physical forces. To neutralize the endothelin effects, a combined ETA/ETB receptor antagonist (LU 302 872) was chosen.

Results. Glucose, but not glycerol, increased mesothelial ET-1 release in a concentration and time-dependent manner ($P < 0.05$ vs. controls). Collagen I RNA synthesis was significantly higher in glucose-challenged cell cultures ($P < 0.05$ vs. controls). The glucose-mediated collagen I RNA synthesis was completely inhibited by adding the combined ETA/ETB receptor antagonist to the medium. Fluid shear stress, but not cellular stretch, led to a significant increase in the mesothelial ET-1 release ($P < 0.005$ vs. controls) and collagen I RNA synthesis ($P < 0.05$ vs. controls). LU 302 872 completely inhibited these effects.

Conclusion. We found that glucose and fluid shear stress are potent stimuli for ET-1 release and collagen I RNA synthesis in a model cellular system. Although our system is highly artificial, our findings raise the hypothesis that similar effects may occur in the peritoneal membranes of peritoneal dialysis patients and suggest that endothelin might be involved.

In long-term peritoneal dialysis, chronic scarring of the peritoneal membrane may result in treatment failure [1]. The mechanisms involved in the initiation and progression of peritoneal fibrosis are not well understood. The dialysate is not a physiologic fluid and may play an important role. The high glucose concentrations may alter mesothelial cell function [2–4] and trigger the release of profibrotic mediators [5–7]. Alternatively, the high osmolarity could play a role [8, 9]. Multiple exchanges must be performed throughout the day with stretching and distension of the mesothelial cells. Conceivably, mechanical forces could be involved. Such forces are important in regulating cell proliferation and differentiation in various cells including endothelial cells [10, 11], vascular smooth muscle cells [12], cardiac myocytes [13], and pulmonary mesothelial cells [14]. We recently reported on the effects of dwell volume and osmolarity of peritoneal dialysate on peritoneal endothelin-1 (ET-1) release in stable peritoneal dialysis patients [15]. We found that increasing dwell volumes from 1500 mL to 2500 mL per dwell led to a significant increase in peritoneal ET-1 release. Furthermore, changing the dialysate glucose concentration from 1.36% to 3.86% activated the peritoneal ET-system. Since endothelin is known to exert substantial profibrotic properties [16, 17], we reasoned that volume and osmolarity-induced ET-1 release might play a role in the process of fibrotic remodeling. To test this notion further, we have conducted a series of experiments in cultured HPMCs.

METHODS

HPMC isolation

We obtained intraoperative specimens of omentum from patients who had given written informed consent (IRB Charité). The pieces (3 to 5 cm²) were washed three times with sterile phosphate-buffered saline (PBS), pH 7.3 (PAA Laboratories GmbH, Linz, Austria), and then

Key words: peritoneal dialysis, peritoneal fibrosis, osmolarity, physical forces, endothelin, endothelin receptor antagonist.

Received for publication December 22, 2002

and in revised form February 7, 2003, May 12, 2003, and June 23, 2003

Accepted for publication July 29, 2003

© 2003 by the International Society of Nephrology

incubated with rotation in 0.25% (wt/vol) trypsin-0.01% (wt/vol) ethylenediaminetetraacetate (EDTA) solution (Sigma Chemical Co., St. Louis, MO, USA) for 20 minutes at 37°C. The tissue was then removed and trypsin solution containing free mesothelial cells was centrifuged at $411 \times g$ for 10 minutes at 4°C. The supernatant was discarded. The cell pellet was washed once with PBS and then suspended in minimum essential medium D-valin (Life Technologies, Grand Island, NY, USA) supplemented with 10% fetal calf serum (FCS) (vol/vol) (Biochrom KG, Berlin, Germany), 100 U/mL penicillin (Biochrom KG), 100 µg/mL streptomycin (Biochrom KG), and 2 mmol/L L-glutamine (Biochrom KG). After seeding into uncoated 75 cm² tissue culture flasks, the cells were maintained in the same medium and incubated at 37°C under an atmosphere of 5% CO₂/95% air in a humidified incubator. The medium was replaced every 2 to 3 days. HPMCs from the second passage were used for the experiments. Confluent cells were polygonal and formed a regular monolayer in light microscopy. HPMCs were characterized by the alkaline phosphatase-antialkaline phosphatase (APAAP) technique. For experiments with endothelin antagonist, we used a combined ETA/ETB receptor antagonist (LU 302 872) in a concentration of 10⁻⁷ mol/L. The manufacturer kindly supplied the compound. The ETA/ETB receptor antagonist LU 302 872 was added to the medium at the same time as administration of the various stresses were started. Confluent HPMCs were incubated in serum-free medium for 24 hours before starting the experiments. Cell viability was assessed by trypan blue. At the end of the experiments viability was more than 90%.

Analyzing osmolar effects

The cells were incubated in a serum-free medium supplemented or not with D-glucose or glycerol. The osmolytes were added to the medium to increase the osmolarity from 290 mOsm/kg (normal osmolarity) to either 300 mOsm/kg (low osmolarity condition) or 500 mOsm/kg (high osmolarity condition). Osmolarities were measured by the freezing point depression method with a micro-osmometer. For the measuring of the ET-1 concentration in the supernatant, conditioned media were collected every 24 hours for 96 hours.

Analyzing physical forces

Reports on fluid-induced shear stress are generally based on laminar flow models. However, in peritoneal dialysis fluid, fluctuation within the abdomen generates nonlaminar fluid shear stress. We attempted to mimic these effects. HPMCs were placed onto a rotating shaker (KS 125 Basic) (IKA Labortechnik, Staufen, Germany) and fluid shear stress was induced by a constant rotation

of the plates (100 rpm). To analyze the effect of cellular stretch, we used a method similar to that described by Wirtz and Dobbs [18]. HPMCs (5×10^4 cells/25 mm diameter well) were seeded into silicone elastomer 6-wells plates (Flex I plates) (Flexercell, McKeesport, PA, USA) and cultured in 2 mL/well medium. The membranes were stretched by applying cyclic air pressure from below. Air pressure was pump-driven and valve-controlled. The frequency of oscillations was set at 50 cycles/min. A 20% increase in the membrane surface area was targeted. The surface area of the elastic membrane was determined by measuring the height of membrane displacement and calculating the increase in surface area from the formula for the area of a sphere. According to Wirtz and Dobbs [18], a 20% increase in the surface area of a silicone membrane translates in an effective increase of cellular surface area of approximately 15%.

Mesothelial cells were exposed to fluid shear stress or cellular stretch for 72 hours.

Reverse transcription-polymerase chain reaction (RT-PCR)

Total RNA from cultured HPMCs was extracted with Trizol (Life Technologies) and reverse transcribed into single-stranded wild-type cDNA (GeneAmp RNA PCR Core Kit) (Perkin-Elmer, Branchburg, NJ, USA) according to the manufacturer's instruction.

The single-stranded wild-type cDNA was subjected to a PCR with modified primer pairs in order to create internal cDNA competitive reference standards (CRS). All DNA sequences used for the design of the PCR primers were obtained from www.ncbi.nlm.nih.gov. The downstream primers were complementary to the mRNA strands. Their 3' ends were linked to an additional sequence, complementary to a region 50 to 70 bp upstream on the mRNA in relation to their 5' starting sequence. This resulted in a 50 to 70 bp deletion in the final PCR-product. The upstream primers were identical in sequence to the mRNA strands except that their 5' ends were coupled with a T7-promotor sequence.

The PCR product was separated on a 2% agarose gel and stained with ethidium bromide. In order to ensure identical PCR conditions for the template and for the CRS, a single-stranded cDNA CRS was generated. Therefore, double-stranded cDNA bands were excised from the gel, eluted using the Quiagen Gel Extraction Kit® (Quiagen, Hilden, Germany) and transcribed into cRNA with the Riboprobe T7 System® (Promega, Madison, WI, USA). The amount of extracted cRNA was determined by ultraviolet spectrophotometry at 260nm, and 0.5µg cRNA were reverse transcribed into internal single-stranded cDNA CRS. Finally, the concentration of single-stranded cDNA was determined.

Table 1. Primer sequences for the construction of internal cDNA control reference standards, for competitive polymerase chain reaction (PCR) as well as for the characterization of the endothelin system [endothelin-1 (ET-1), ETA and ETB receptor, endothelin-converting enzyme]. Internal cDNA competitive reference standards (CRS) were constructed using modified primers. The 5' end of the upstream-primer (sense, sequence 1) was coupled with a T7-promoter sequence. The 3' end of the downstream-primer (antisense, sequence 1) was linked to an additional sequence (sequence 2), complementary to a region 50 to 70 bp upstream

Primer Nucleotide-Sequence			First nucleotide of the primer sequence bp	Estimated PCR product size bp
Collagen I	Sense	T7 promoter		
		Sequence 1	5'-AAT TTA ATA CGA CTC ACT ATA GGG A-3'	
	Antisense	Sequence 1	5'-CG CAC ATG CCG TGA CTT GAG ACT CA-3'	606
		Sequence 2	5'-CCA CCG ATG TCC AAA GGT GCA AT-3'	1155
GAPDH	Sense	T7 promoter		
		Sequence 1	5'-AAT TTA ATA CGA CTC ACT ATA GGG A-3'	
	Antisense	Sequence 1	5'-CG TCT TCA CCA CCA TGG AGA A-3'	375
		Sequence 2	5'-CCA GTG AGC TTC CCG TTC AGC TC-3'	742
ET-1	Sense	T7 promoter		
		Sequence 1	5'-AAT TTA ATA CGA CTC ACT ATA GGG A-3'	
	Antisense	Sequence 1	5'-CG TCT TCA CCA CCA TGG AGA A-3'	375
		Sequence 2	5'-TCC GGG AAA CTG TGG CGT GAT GGC 3'	648
ETA rez	Sense	T7 promoter		
		Sequence 1	5'-AAT TTA ATA CGA CTC ACT ATA GGG A-3'	
	Antisense	Sequence 1	5'-CG TCT TCA CCA CCA TGG AGA A-3'	375
		Sequence 2	5'-TCC GGG AAA CTG TGG CGT GAT GGC 3'	648
ETB rez	Sense	T7 promoter		
		Sequence 1	5'-AAT TTA ATA CGA CTC ACT ATA GGG A-3'	
	Antisense	Sequence 1	5'-CG TCT TCA CCA CCA TGG AGA A-3'	375
		Sequence 2	5'-TCC GGG AAA CTG TGG CGT GAT GGC 3'	648
ECE	Sense	T7 promoter		
		Sequence 1	5'-AAT TTA ATA CGA CTC ACT ATA GGG A-3'	
	Antisense	Sequence 1	5'-CG TCT TCA CCA CCA TGG AGA A-3'	375
		Sequence 2	5'-TCC GGG AAA CTG TGG CGT GAT GGC 3'	648

Abbreviations are: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ET-1, endothelin-1; ECE, endothelin-converting enzyme.

All DNA sequences used for the design of the PCR primers were obtained from www.ncbi.nlm.nih.gov. All PCR products were sequenced to confirm identity.

Constant amounts of single-stranded wild-type cDNA (0.5 µL) together with serial dilutions [1:3 for collagen I, 1:5 for glyceraldehyde-3-phosphate dehydrogenase (GAPDH)] of single-stranded cDNA CRS (starting concentrations, 2 µg) were coamplified in a PCR mixture for which we used non-modified primer pairs (Table 1).

PCR products were then directed to agarose gel electrophoresis (2%), visualized by ethidium bromide staining, and photographed with a digital camera (Kodak DC 40, Rochester, NY, USA). Two different bands were distinguishable due to the smaller size of the cDNA CRS as compared to target cDNA. As charged by comparison with a 100 bp DNA-ladder (Rapidozym, Berlin, Germany), PCR products proved to be consistent with their predicted size. Sequencing of the PCR products confirmed the identity of the amplified target genes (Replicon, Berlin, Germany). Band intensities were densitometrically analyzed through the use of the One-Dimensional Image Analysis Software® (Kodak Digital Science™). The relative amount of target mRNA was calculated through the use of a log-log scale plot of the ratio of PCR products (cDNA CRS band intensities/target cDNA band intensities) versus the known amount of cDNA CRS used in the competitive PCR reactions. When target and CRS values were equivalent, the amount of target was equal to the known amount of internal CRS. In order to exclude nonspecific changes in total mRNA synthesis, the value of target mRNA was normalized to expression of GAPDH mRNA. Negative controls were

performed with target cDNA only, with cDNA CRS only and without cDNA in order to exclude contaminating DNA.

Characterization of the mesothelial endothelin system by PCR

All DNA sequences used for the design of the PCR primers were obtained from www.ncbi.nlm.nih.gov.

Table 1 provides detailed information on primer sequences, the first nucleotide of the primer sequence as well as the estimated product size. All PCR products were sequenced to confirm identity.

STATISTICS

Statistical analysis was carried out with the SPSS System (Release 10.0). Only nonparametric tests were used for comparison. The Mann-Whitney *U* test was used for unpaired data, the Wilcoxon signed rank test was used for paired data. Results are expressed as mean ± SE. A *P* value <0.05 was regarded as significant.

RESULTS

Characterization of cultures of HPMC

Confluent cells were polygonal and formed a regular monolayer in light microscopy. They expressed cytokeratin and vimentin but failed to react with the endothelial marker von Willebrand factor.




Fig. 1. Electron-microscopic examination of mesothelial cells. (A) Mesothelial cells express a huge number of microvilli on the surface. Micropinocytotic vesicles can be observed on the cell membrane. In the cytoplasm, numerous organelles can be detected such as the endoplasmic reticulum, lamellar bodies, mitochondria, and the Golgi complex. (B) Mesothelial cells are tightly bound to each other by cell interaction. In this scan a tight junction is shown.

By electron microscopy, mesothelial cells showed apical microvilli and tight junctions (Fig. 1).

Characterization of mesothelial endothelin system by PCR

Mesothelial cells expressed genes for ET-1, the ET-A and ET-B receptors, as well as for the endothelin-converting enzyme.

Osmotic agents and mesothelial ET-1 release

Confluent mesothelial cell cultures exposed to glucose media showed a marked increase in ET-1 release compared to glycerol or unchallenged control medium (Fig. 2). High glucose (500 mOsm/kg) medium led to the highest ET-1 release and values at 72 and 96 hours differed significantly from that of glycerol (500 mOsm/kg) challenged or osmolyte-free medium (290 mOsm/kg) ($P < 0.05$). Low glucose (300 mOsm/kg) also had a tendency toward increasing ET-1 values over time ($0.1 > P > 0.05$). The percent increase in ET-1 release for high glucose was greater than that for high glycerol medium compared to osmolyte-free medium. At 72 hours, mean values were $78\% \pm 18\%$ for glucose and $5\% \pm 9\%$ for glycerol ($P < 0.05$).

Fluid shear stress

Fluid shear stress led to increased the mesothelial ET-1 release compared to nonstressed HPMCs. Mean ET-1 values at 72 hours were 3.3 ± 0.4 fmol/mL for HPMCs exposed to continuous fluid shear stress and 2.1 ± 0.4 fmol/mL for nonstressed HPMCs ($P < 0.005$). Combining fluid shear stress with high glucose medium (500 mOsm/kg) did




Fig. 2. Osmolar effects on human peritoneal mesangial cells (HPMC) endothelin-1 (ET-1) release. Glucose led to a concentration and time-dependent increase in mesothelial ET-1 release. Values at 72 and 96 hours differed significantly ($N = 10$ for each experiment). * $P < 0.05$ from standard and glycerol medium.

not increase ET-1 release further. Mean values were 3.0 ± 0.4 fmol/mL. Blocking the ETA and ETB receptors during the fluid shear stress experiments led to a significant increase in mesothelial ET-1 release ($P < 0.05$) (Fig. 3).

Cell stretch

Mesothelial cell cultures grown in standard medium and exposed to cyclic cellular stretch tended to show higher ET-1 values compared to nonstressed HPMCs ($0.1 > P > 0.05$). Mean values were 2.1 ± 0.2 fmol/mL for cellular stretch compared to 1.8 ± 0.4 fmol/mL for nonstressed cell cultures. Combining high glucose medium




Fig. 3. Endothelin-1 (ET-1) release of human peritoneal mesangial cells (HPMC) exposed to continuous fluid shear stress (72 hours). Adding the combined ETA/ETB receptor antagonist LU 302872 to the culture medium led to a significant increase in ET-1 release ($N = 8$ for each experiment). * $P < 0.05$.




Fig. 4. Endothelin-1 (ET-1) release of human peritoneal mesangial cells (HPMC) exposed to high glucose medium (500 mOsm/L) with and without cellular stretch. High glucose medium in combination with cellular stretch led to a significantly higher ET-1 release compared to the unstretched controls ($P < 0.05$).

and cellular stretch led to a significant increase in the mesothelial ET-1 release compared to nonstressed cells grown in high glucose medium ($P < 0.05$) (Fig. 4).

Collagen I RNA synthesis

HPMCs exposed to high glucose medium showed a mean increase of 118% (20% to 320%) in collagen I RNA synthesis compared to cells grown in standard medium ($P < 0.05$) (Fig. 5A). Glycerol led to a 23% (–49% to 75%) increase in collagen I RNA synthesis compared to unchallenged cells (NS) (Fig. 5B). Adding the combined ETA/ETB receptor antagonist LU 302 872 to mesothelial cell cultures incubated with high glucose media com-




Fig. 5. Human peritoneal mesangial cells (HPMC) cultures. (A) HPMC cultured in high glucose medium (500 mOsm/kg) showed a significant increase in collagen I RNA synthesis compared to nonstressed controls. This effect was inhibited by the ETA/ETB antagonist LU 302 872. The percent increase in HPMC collagen I RNA release differed significantly between both groups ($N = 3$ to 8 for each experiment). * $P < 0.05$. (B) Glycerol (500 mOsm/kg) had almost no effect on HPMC collagen I RNA synthesis ($N = 3$ to 8 for each experiment, NS).

pletely inhibited collagen I RNA synthesis (Fig. 5A). The combined ETA/ETB receptor antagonist had no effect in HPMC cultures grown in high glycerol or osmolyte-free medium (Fig. 5B). RT-PCR for collagen I RNA of HPMCs cultured in high glucose was greater than control medium (Fig. 6). Fluid shear stress increased collagen I RNA synthesis in HPMCs by 52% (19% to 110%) compared to nonstressed cells ($P < 0.05$). Adding the combined ETA/ETB receptor antagonist to cell cultures exposed to fluid shear stress reduced ($P < 0.05$) collagen I RNA synthesis to values of nonstressed HPMCs (Fig. 7). The combination of fluid shear stress and high glucose medium tended to achieve slightly higher values for




Fig. 6. Reverse transcription-polymerase chain reaction (RT-PCR) for collagen I RNA for human peritoneal mesangial cells (HPMC) cultured in high glucose (500 mOsm/kg) and control medium (290 mOsm/kg).




Fig. 7. Human peritoneal mesangial cells (HPMC) exposed to continuous fluid shear stress (72 hours) showed a significant increase in collagen I RNA synthesis compared to nonstressed controls. This effect was inhibited by the ETA/ETB receptor antagonist LU 302 872. The percent increase in HPMC collagen I RNA release differed significantly between both groups ($N = 8$ for each experiment). * $P < 0.05$.

collagen I RNA synthesis ($0.1 > P > 0.05$). The effects of glycerol in combination with fluid shear stress were similar to those obtained with osmolyte free medium. Cellular stretch, either alone or in combination with glucose, had no significant impact on collagen I RNA synthesis.

DISCUSSION

We found that glucose increases HPMC ET-1 release in a time-dependent manner. These effects were observed at osmolarities in the range of those of commercial dialysis fluids. The effects seemed to be glucose specific since high glycerol had no impact on ET-1. High glucose, but not glycerol, also increased HPMC collagen I RNA synthesis. The combined ETA/ETB receptor antagonist inhib-

ited the increase. Fluid shear stress also increased HPMC ET-1 release and collagen I RNA synthesis. The ETA/ETB receptor antagonist inhibited the effect.

In good agreement with other studies [19–21], we could also demonstrate that high glucose concentrations induce synthesis of transforming growth factor- β (TGF- β) in HPMCs (data not shown). TGF- β is a well-known stimuli of endothelin [22]. Thus, the observed activation of the endothelin system might be, at least partially, secondary to the enhanced TGF- β release.

ET-1 has shown to directly stimulate collagen I synthesis in vascular smooth muscle cells from coronary arteries and the aorta [17]. Furthermore, ET-1 stimulates fibrogenic activity in various organs by regulating production and turnover of matrix components [23]. ET-1 is implicated in fibrotic diseases such as systemic sclerosis [24, 25], pulmonary fibrosis [26], and hepatic fibrosis [27]. Moreover, ET-1 overexpression in transgenic mice [16] and ET-2 in transgenic rats [28] causes renal fibrosis. These observations would support a possible mechanistic role of ET-1 in peritoneal fibrosis. We recently observed that by increasing the dwell volume or the glucose-induced osmolarity of the peritoneal dialysis fluid, we could activate the peritoneal paracrine endothelin system [15]. Our present findings suggest glucose and fluid shear stress are the primary triggers. In addition, we present evidence that links the activated mesothelial endothelin system to the profibrotic process within the peritoneum. Glucose is known as a potent stimulant for the paracrine ET-system [16, 29, 30]. Furthermore, high glucose concentrations may enhance ET-1 promoter activity in primary mesangial cells [31]. In experimental animal models of diabetes, blocking the ET-system has shown to ameliorate glucose-induced end organ damage [32–34].

The above-mentioned studies are especially important since the structural alterations of the peritoneum during peritoneal dialysis are very similar to vascular and tissue alteration seen in diabetes. The tissue alterations during long-term peritoneal dialysis include a thickening and replication of basement membrane of the peritoneal capillaries, angiogenesis as well as a thickening and fibrotic remodeling of the submesothelial tissue [35, 36]. Peritoneal dialysis has even been considered as an experimental model for diabetic microangiopathy in humans [37].

The exact mechanisms on how glucose induces fibrotic remodeling and basement membrane thickening are still under investigation. Evidence from in vitro studies of vascular cells suggest that an increased activation of protein kinase C (PKC) is intricately involved in this process [38, 39]. PKC activation has been associated with the activation of vasoactive factors such as vascular endothelial growth factor and ET-1 [40]. Hence, it is conceptually possible that some of the actions of PKC in hyperglycemia are mediated via ET-1. Chen et al [41] demonstrated

that endothelial cells, cultured in 25 mmol/L glucose, up-regulated the expression of extracellular matrix proteins via ET-1 through activation of nuclear factor-kappa B (NF- κ B) and activating protein-1 (AP-1). ET-receptor antagonism prevented extracellular matrix mRNA expression [34].

Also, vascular permeability seem to be effected by alteration of the endothelin system. This is of particular importance since vascular permeability directly impacts on transport characteristics of the peritoneal membrane during peritoneal dialysis [42]. Chen et al [43] investigated ET-1 expression in human umbilical vein endothelial cells (HUVEC) in response to glucose and the functional significance of these mechanisms. Permeability across HUVEC, grown in medium containing either low (5 mmol/l) or high (25 mmol/l) D-glucose were investigated. L-glucose was used as a control. Increased transendothelial permeability was noted in cells cultured in high glucose or when the cells grown in low (physiologic) glucose were incubated with ET-1 but not when they were incubated with L-glucose. Increased permeability was associated with increased ET-1, ETA, and ETB mRNA expression and augmented ET-1 immunoreactivity [43].

How fluid shear stress is converted into biochemical signals in the peritoneum is uncertain. Mechanical forces can affect the permeability of the cell membrane to various ions, such as Ca^{2+} or K^{+} [44, 45]. Mechanical stimulation can lead to cell depolarization by activating voltage sensitive channels [46]. Moreover, mechanosensitive ion channels have recently been identified [47] and characterized. Fluid shear stress had a strong impact on ET-1 release and collagen I RNA synthesis, while cellular stretch only had only a modest effect. Cellular stretch may represent a more physiologic stress for the intra-abdominal mesothelial monolayer. Mesothelial cells are constantly exposed to cellular stretch during bowel movements or breathing which may have led to cellular stretch adaptation.

ETA/ETB receptor blockade was effective in blocking glucose-related and fluid shear stress-related effects in our study. ETA receptor and combined receptor antagonists have been effective in ameliorating ET-1-related effects in several animal models of fibrosis [48, 49]. In some of these studies, the receptor blockade was shown to involve reduced expression of growth factors, extracellular matrix deposition, and decreasing matrix metalloproteinase activity [50, 51].

We are aware that our study has limitations. Although glucose-related effects in peritoneal dialysis are easily appreciated, we have not shown for certain that fluid shear stress is a common phenomenon in peritoneal dialysis patients. Animal models of peritoneal dialysis should be the next step to address the impact of mechanical forces on the induction of peritoneal fibrosis more specifically.

Nevertheless, we suggest the possibility that such stressors may be clinically relevant. We raise the hypothesis that high glucose combined with mechanical forces may stimulate collagen I RNA synthesis. Adding a combined ETA/ETB receptor antagonist that inhibited the effect. Although this approach appeared very effective, we did not examine other possible mediators that may nonetheless be operative such as monocyte chemoattractant protein-1, fibronectin, or advanced glycation end products. We believe our findings may have clinical relevance and application. If a locally applied ETA/ETB receptor antagonist were able to indeed ameliorate peritoneal injury in peritoneal dialysis patients, or possibly prolong the utility of the therapy, such a treatment would be of great value.

ACKNOWLEDGMENTS

We thank Dr. Kerstin Dell for her technical assistance in performing RT-PCR and Prof. F. Luft for critically reviewing the manuscript. We also thank Dr. Raschack (Knoll AG, Ludwigshafen, Germany) for kindly providing the combined ETA/ETB receptor antagonist LU 302 872. This study was supported by a grant from Fresenius Medical Care and in part also by a grant from the Deutsche Forschungsgemeinschaft (HO 1665/5-1).

Reprint requests to Dr. med. Stanislaw Morgera, Universitätsklinikum Charité der Humboldt Universität zu Berlin, Medizinische Klinik mit Schwerpunkt Nephrologie am CCM, Schumannstr. 20-21, 10098 Berlin, Germany.

E-mail: stanislaw.morgera@charite.de

REFERENCES

1. PLUM J, HERMANN S, FUSCHOLLER A, et al: Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. *Kidney Int* 59(Suppl 78): S42-S47, 2001
2. LEE HB, CHUNG SH, CHU WS, et al: Peritoneal dialysis in diabetic patients. *Am J Kidney Dis* 38(4 Suppl 1):S200-S203, 2001
3. LEE SK, KIM BS, YANG WS, et al: High glucose induces MCP-1 expression partly via tyrosine kinase-AP-1 pathway in peritoneal mesothelial cells. *Kidney Int* 60:55-64, 2001
4. JORRES A, BENDER TO, WITOWSKI J: Glucose degradation products and the peritoneal mesothelium. *Perit Dial Int* 20(Suppl 5):S19-S22, 2000
5. OGATA S, YORIOKA N, KOHNO N: Glucose and prednisolone alter basic fibroblast growth factor expression in peritoneal mesothelial cells and fibroblasts. *J Am Soc Nephrol* 12: 2787-2796, 2001
6. HUNG KY, CHEN CT, HUANG JW, et al: Dipyridamole inhibits TGF-beta-induced collagen gene expression in human peritoneal mesothelial cells. *Kidney Int* 60:1249-1257, 2001
7. CRONAUER MV, STADLMANN S, KLOCKER H, et al: Basic fibroblast growth factor synthesis by human peritoneal mesothelial cells: Induction by interleukin-1. *Am J Pathol* 155:1977-1984, 1999
8. WITOWSKI, WISNIEWSKA J, KORYBALSKA K, et al: Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. *J Am Soc Nephrol* 12:2434-2441, 2001
9. KUMANO K, SCHILLER B, HJELLE JT, MORAN J: Effects of osmotic solutes on fibronectin mRNA expression in rat peritoneal mesothelial cells. *Blood Purif* 14:165-169, 1996
10. DAVIES PF, BARBEE KA, VOLIN MV, et al: Spatial relationships in early signaling events of flow-mediated endothelial mechanotransduction. *Annu Rev Physiol* 59:527-549, 1997
11. RESNICK N, GIMBRONE MA JR: Hemodynamic forces are complex regulators of endothelial gene expression. *FASEB J* 9:874-882, 1995

12. OSOL G: Mechanotransduction by vascular smooth muscle. *J Vasc Res* 32:275–292, 1995
13. SADOSHIMA J, IZUMO S: The cellular and molecular response of cardiac myocytes to mechanical stress. *Annu Rev Physiol* 59:551–571, 1997
14. LIU M, POST M: Invited review: Mechanochemical signal transduction in the fetal lung. *J Appl Physiol* 89:2078–2084, 2000
15. MORGERA S, KUCHINKE S, BUDDE K, et al: Volume stress-induced peritoneal endothelin-1 release in continuous ambulatory peritoneal dialysis. *J Am Soc Nephrol* 10:2585–2590, 1999
16. HOCHER B, THÖNE-REINEKE C, ROHMEISS P, et al: Endothelin-1 transgenic mice develop renal cysts, interstitial fibrosis and glomerulosclerosis but not hypertension. *J Clin Invest* 99:1380–1389, 1997
17. RIZVI MAD, KATWA L, SPADONE DP, MYERS PR: The effects of endothelin-1 on collagen type I and type II synthesis in cultured porcine coronary artery vascular smooth muscle cells. *J Mol Cell Cardiol* 28:243–253, 1996
18. WIRTZ HR, DOBBS LG: Calcium mobilization and exocytosis after one mechanical stretch of lung epithelial cells. *Science* 250:1266–1269, 1990
19. HA H, YU MR, LEE HB: High glucose-induced PKC activation mediates TGF-beta 1 and fibronectin synthesis by peritoneal mesothelial cells. *Kidney Int* 59:463–470, 2001
20. WANG T, CHEN YG, YE RG, et al: Effect of glucose on TGF-beta 1 expression in peritoneal mesothelial cells. *Adv Perit Dial* 11:7–10, 1995
21. MEDCALF JF, WALLS J, PAWLUCZYK IZ, HARRIS KP: Effects of glucose dialysate on extracellular matrix production by human peritoneal mesothelial cells (HPMC): The role of TGF-beta. *Nephrol Dial Transplant* 16:1885–1892, 2001
22. MIYAUCHI T, MASAKI T: Pathophysiology of endothelin in the cardiovascular system. *Annu Rev Physiol* 61:391–415, 1999
23. GUARDA E, KATWA LC, MYERS PR, et al: Effects of endothelins on collagen turnover in cardiac fibroblasts. *Cardiovasc Res* 27:2130–2134, 1993
24. VANCHEESWARAN R, AZAM A, BLACK CM, DASHWOOD MR: Localisation of endothelin-1 and its binding sites in scleroderma skin. *J Rheumatol* 21:1268–1276, 1994
25. KNOCK GA, TERENGI G, BUNKER CB, et al: Characterisation of endothelin-binding sites in human skin and their regulation in primary raynaud's phenomenon and systemic sclerosis. *J Invest Dermatol* 101:73–78, 1993
26. ABRAHAM DJ, VANCHEESWARAN R, DASHWOOD MR, et al: Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma associated fibrotic lung disease. *Am J Pathol* 151:831–841, 1997
27. ROCHEY DC, CHUNG JJ: Endothelin antagonism in experimental hepatic fibrosis. *J Clin Invest* 98:1381–1388, 1996
28. HOCHER B, LIEFELDT L, THÖNE-REINEKE C, et al: Characterization of the renal phenotype of transgenic rats expressing the human endothelin-2 gene. *Hypertension* 28:196–201, 1996
29. YAMAUCHI T, OHNAKA K, TAKAYANAGI R, et al: Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells. *FEBS Lett* 267:16–18, 1990
30. DENG DX, EVANS T, MUKHERJEE K, et al: Diabetes induced dysfunction in the retina: Role of endothelins. *Diabetologia* 42:1228–1234, 1999
31. HARGROVE GM, DUFRESNE J, WHITESIDE C, et al: Diabetes mellitus increases endothelin-1 gene transcription in rat kidney. *Kidney Int* 58:1534–1545, 2000
32. EVANS T, DENG DX, CHEN S, CHAKRABARTI S: Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats. *Diabetes* 49:662–666, 2000
33. HOCHER B, SCHWARZ A, REINBACHER D, et al: Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. *Nephron* 87:161–169, 2001
34. CHEN S, KHAN ZA, CUKIERNIK M, CHAKRABARTI S: Differential activation of NF- κ B and AP-1 in mediating endothelin dependent increased fibronectin synthesis in target organs of diabetic complications. *Am J Physiol Endocrinol Metab* 284:E1089–E1097, 2003
35. DOBBIE JW, LLOYD JK, GALL CA: Categorization of ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients. *Adv Perit Dial* 6:3–12, 1990
36. MATEJUSEN MA, VAN DER WAL AC, HENDRIKS PM, et al: Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. *Perit Dial Int* 19:517–525, 1999
37. DI PAOLO N, SACCHI G: Peritoneal Vascular changes in continuous ambulatory peritoneal dialysis (CAPD): An in vivo model for the study of diabetic microangiopathy. *Perit Dial Int* 9:41–45, 1989
38. KOYA D, KING GL: Protein kinase C activation and the development of diabetic complications. *Diabetes* 47:859–866, 1998
39. KOYA D, JIROUSEK MR, LIN YW, et al: Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanooids in the glomeruli of diabetic rats. *J Clin Invest* 100:115–126, 1997
40. KOYA D, KING GL: Protein kinase C activation and the development of diabetic complications. *Diabetes* 47:859–866, 1998
41. CHEN S, MUKHERJEE S, CHAKRABORTY C, CHAKRABARTI S: High glucose induced, endothelin dependent, extracellular matrix protein synthesis is mediated via nuclear factor-kappa B and activating protein-1. *Am J Physiol Cell Physiol* 284:C263–C272, 2003
42. DOUMA CE, DE WAART DR, STRUIJK DG, KREDIET RT: The nitric oxide donor nitroprusside intraperitoneally affects peritoneal permeability in CAPD. *Kidney Int* 57:1885–1892, 1997
43. CHEN S, APOSTOLOVA MD, CHERIAN MG, CHAKRABARTI S: Interaction of endothelin-1 with vasoactive factors in mediating glucose-induced increased permeability in endothelial cells. *Lab Invest* 80:1311–1321, 2000
44. SCHILLING WP, MO M, ESKIN SG: Effect of shear stress on cytosolic Ca²⁺ of calf pulmonary artery endothelial cells. *Exp Cell Res* 198:31–35, 1992
45. BIALECKI RA, KULIK TJ, COLUCCI WS: Stretching increases calcium influx and efflux in cultured pulmonary arterial smooth muscle cells. *Am J Physiol* 263:L602–L606, 1992
46. BOITANO S, WOODRUFF ML, DIRKSEN ER: Evidence for voltage-sensitive, calcium-conducting channels in airway epithelial cells. *Am J Physiol* 269:C1547–C1556, 1995
47. SUKHAREV SI, BLOUNT P, MARTINAC B, et al: A large-conductance mechanosensitive channel in *E. coli* encoded by mscL alone. *Nature* 368:265–268, 1994
48. PARK JB, SCHIFFRIN EL: Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: Role of endothelin-1. *Am J Hypertens* 15:164–169, 2002
49. BOFFA JJ, THARAUX PL, DUSSAULE JC, CHATZIANTONIOU C: Regression of renal vascular fibrosis by endothelin receptor antagonism. *Hypertension* 37:490–499, 2001
50. TOSTES RC, TOUYZ RM, HE G, et al: Endothelin a receptor blockade decreases expression of growth factors and collagen and improves matrix metalloproteinase-2 activity in kidneys from stroke-prone spontaneously hypertensive rats. *J Cardiovasc Pharmacol* 39:892–900, 2002
51. CHO JJ, HOCHER B, HERBST H, et al: An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. *Gastroenterology* 118:1169–1178, 2000
52. RUBIN LJ, BADESCH DB, BARST RJ, et al: Bosentan therapy for pulmonary arterial hypertension. *N Engl J Med* 346:896–903, 2002